10-Q · May 14, 2026
Inhibrx reported a Q1 2026 net loss of $33.4 million, an improvement of 23% compared to a net loss of $43.3 million in Q1 2025. Operating expenses decreased significantly by 28% due to reduced research and development…
Earnings analysis · 10-Q
INBX earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q does not include the income statement, balance sheet, cash-flow statement, or segment disclosures, so current-period revenue, margins, EPS, liquidity, debt, working capital, and free cash flow cannot…
Read full summary
The extracted 10-Q does not include the income statement, balance sheet, cash-flow statement, or segment disclosures, so current-period revenue, margins, EPS, liquidity, debt, working capital, and free cash flow cannot be quantified from the provided filing text. Operationally, the company continues to advance 2 therapeutic candidates, and its ozekibart BLA is under FDA review. The principal updated risks are regulatory review uncertainty, Form 483 inspection observations, and the history of a grade 5 hepatotoxicity event that previously triggered a partial clinical hold.
What stood out
-
Pipeline remains focused on 2 candidates
The company reported that 2 therapeutic candidates, ozekibart (INBRX-109) and INBRX-106, are currently in active clinical trials, while its BLA for ozekibart is under FDA review.
-
Controls operating effectively
Management stated that disclosure controls and procedures were operating effectively at the reasonable assurance level as of June 30, 2026.
-
No material control changes
The filing states that there were 0 material changes to internal control over financial reporting during the quarter ended June 30, 2026.
What to watch
-
No products and approval uncertainty
The company has 0 products on the market and depends on regulatory approval and successful commercialization of its therapeutic candidates to achieve profitability. Its ozekibart BLA remains under FDA review, with no assurance of approval on the expected timeline or at all.
-
FDA inspection observations
FDA clinical inspections related to the ozekibart BLA generated Form 483 observations for the company and some ChonDRAgon investigators. Although corrective and preventive actions have been implemented, the observations could delay review or result in a complete response letter.
-
Clinical safety and trial-delay risk
The ChonDRAgon trial experienced a grade 5 hepatotoxicity event in early 2023 that triggered protocol stopping rules and a partial clinical hold; the FDA lifted the hold in April 2023 after protocol amendments.
Management's outlook
No quantitative revenue or EPS outlook was provided in the extracted 10-Q. The filing does not provide explicit forward guidance.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.